08:30-09:00 - REGISTRATION

09:00-09:30 - WELCOME AND OPENING SESSION / REMARKS
Rui Henrique, Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal
Julio E. Celis, Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark
Marta Temido, Minister for Health, Portugal
Stella Kyriakides, European Commissioner for Health and Food Safety, European Union
Manuel Heitor, Minister for Science, Technology and Higher Education, Portugal
Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education & Youth, European Union

09:30-09:50 - PRESENTATION OF “PORTO DECLARATION ON CANCER RESEARCH” AND KEY NOTE SPEECHES:
Anton Berns, President of the EACS: Infrastructures to sustain the EU cancer mission, Brussels, Belgium
Walter Ricciardi, President, EU Cancer Mission Board, Brussels, Belgium

09:50-10:10 - COFFEE BREAK

10:10-12:10 - SESSION 1. INFRASTRUCTURE FOR TRANSLATIONAL RESEARCH
Chair: Ulrik Ringborg, Cancer Center Karolinska, Stockholm, Sweden

Presentations:
> Basic/preclinical research: Generating proof of concept clinical trials is the engine for translational cancer research | Alexander Eggermont, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
> The Comprehensive Cancer Centre: An essential infrastructure component | Simon Oberst, Cancer Research UK, Cambridge Center, Cambridge, UK
> Molecular and digital pathology is essential to develop personalized/precision cancer medicine | Fátima Carneiro, University of Porto, Porto, Portugal
> Immunotherapy: An expanding treatment modality | Laurence Zitvogel, Gustave Roussy Cancer Campus, Grand Paris, France
> Liquid biopsies: Expanding diagnostic procedures for both therapeutics and prevention | Olli Kallioniemi, Science for Life Laboratory, Stockholm, Sweden
> Acquisition of clinical and biological data: Implementation of computational sciences (Artificial Intelligence) | Jan Korbøl, European Molecular Biology Laboratory, Heidelberg, Germany
> EC Knowledge Centre on Cancer | Guy Van den Eede, European Commission, Brussels, Belgium
Debate (to be confirmed):
> Douglas Hanahan, École polytechnique fédérale de Lausanne - EPFL, Lausanne, Switzerland
> Stefan Fröhling, National Center for Tumour Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany
> Péter Nagy, National Institute of Oncology, Budapest, Hungary
> Ken Mastris, President of European Cancer Patient Coalition (ECPC), Brussels, Belgium
> Raquel Seruca, Institute for Investigation and Innovation in Health (I3S), Porto, Portugal

12:10-12:50 - Lunch

12:50-14:40 - SESSION 2. INFRASTRUCTURE FOR CLINICAL AND PREVENTION TRIALS
Chair: Josep Taberner, Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain

Presentations:
> Quality assurance of clinical trials structures: harmonisation of technical requirements to support multinational institutional collaborations in next-generation clinical trials | Denis Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
> Molecular pathology for patient stratification in multicentre clinical trials | Paolo Nuciforo, Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain
> Genomics: From discovery to bench-side genomics | Emile Voest, The Netherlands Cancer Institute, Amsterdam, The Netherlands
> Modern Imaging in Oncology | Regina Beets-Tan, The Netherlands Cancer Institute, Amsterdam, The Netherlands
> Repeated biopsies (fine needle aspiration and liquid biopsies), biobanking and clinical trials registries with clinical and biological information | Benjamin Besse, Institute Gustave-Roussy, Grand Paris, France
> Development of innovative radiotherapy trials | Vincenzo Valentini, Policlinico Gemelli, Rome, Italy
> Coordination of clinical trials activities from proof-of-concept trials to practice-changing clinical trials: added value compared to present treatments | Elena Garralda, Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain
> New concepts and opportunities in cancer prevention clinical trials | Elisabete Wiederpass, International Agency for Research on Cancer, Lyon, France
> The Molecular Tumour Board: a critical infrastructure for delivery of Precision Medicine | Júlio Oliveira, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

Debate (to be confirmed):
> Bettina Ryll, Cancer Mission Board member, Uppsala, Sweden
> Susan Galbraith, AstraZeneca, Cambridge, UK
> Fátima Cardoso, Champalimaud Clinical Center, Lisbon, Portugal
> José Carlos Machado, Institute for Investigation and Innovation in Health (I3S), Porto, Portugal

14:40-16:30 - SESSION 3. INFRASTRUCTURE FOR OUTCOMES RESEARCH
Chair: Joachim Schüz, International Agency for Research on Cancer, Lyon, France

Presentations:
> Outcomes research Infrastructure to support the development of primary prevention | Joachim Schüz, International Agency for Research on Cancer, Lyon, France
Outcomes research infrastructure to support the development of cancer screening
| Partha Basu, International Agency for Research on Cancer, Lyon, France

Outcomes research infrastructure to support the assessment of clinical effectiveness of therapeutic innovations | Nils Wilking, Karolinska Institutet, Stockholm, Sweden

Infrastructure support for cancer specific Health-Related Quality of Life research | Karen Steindorf, National Center for Tumour Diseases and German Cancer Research Center, Heidelberg, Germany

Outcomes research infrastructure for survivorship research | Françoise Meunier, Former head of the European Organisation for Research and Treatment of Cancer, Brussels, Belgium

Health economics as an integrated part of the cancer research continuum for prevention and therapeutics | Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden

A case study: outcomes implementation and measurement in lung cancer | Marta Soares, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

Debate (to be confirmed):
| Jose M. Martin-Moreno, University of Valencia, Spain

| Florian Alexandru Nicula, Institute of Oncology, Cluj-Napoca, Romania

| Maja Primic-Zakelj, Institute of Oncology, Ljubljana, Slovenia & Formerly Head of Epidemiology and Cancer Registry, Ljubljana, Slovenia

16:30-17:05 - SESSION 4. EU-USA CANCER RESEARCH COOPERATION
Chair: Michael Baumann, German Cancer Research Centre (DKFZ), Heidelberg, Germany

Strategic development of precision cancer medicine in the US | Richard Schilsky, Past President and former Chief Medical Officer, American Society of Clinical Oncology, Alexandria, VA, USA

17:05-17:15 - CLOSING REMARKS
| António Sousa Pereira, Rector, University of Porto, Porto, Portugal

| Rui Henrique, Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

| Julio E. Celis, Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark

| Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education & Youth, European Union

| Manuel Heitor, Minister for Science, Technology and Higher Education, Portugal